Homegrown mRNA players BioNTech and CureVac have signed on to supply Germany with vaccines against future health emergencies for years to come.
Germany will pay upward of 2.86 billion euros ($3.14 billion) to lock up local vaccine production capacity through 2029, Reuters reports, citing the country’s economy ministry. Wednesday, the German government approved plans to sign contracts with mRNA specialist BioNTech plus the partnership between CureVac and GlaxoSmithKline. Also involved are contract manufacturers Wacker, CordenPharma, Celonic and IDT, the news outlet said.
While BioNTech has done gangbusters with its Pfizer-partnered COVID-19 vaccine Comirnaty, mRNA compatriot CureVac has had a decidedly tougher go of things. CureVac in September cut the cord on manufacturing contracts with Wacker and Celonic in the wake of late-stage data showing its first-generation COVID-19 vaccine was just 48% effective.
The cancellations wouldn’t affect CureVac’s deals with Rentschler Biopharma or Novartis for the production and formulation of mRNA, and the company continues to plug away on a second-generation COVID shot with GlaxoSmithKline.